{
    "2020-10-13": [
        [
            {
                "time": "2023-11-01",
                "original_text": "张磊再出手：高瓴资本斥资10亿入股A股上市公司凯莱英",
                "features": {
                    "keywords": [
                        "高瓴资本",
                        "凯莱英",
                        "医药股",
                        "定增"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-11-01",
                "original_text": "焦点分析 | 10亿元拿下凯莱英，高瓴重金押注的CXO有何魅力？",
                "features": {
                    "keywords": [
                        "高瓴",
                        "凯莱英",
                        "CXO",
                        "医药行业"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-11-01",
                "original_text": "高瓴资本再出手入股凯莱英，10亿狂买600亿医药股",
                "features": {
                    "keywords": [
                        "高瓴资本",
                        "凯莱英",
                        "医药股",
                        "投资"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-11-01",
                "original_text": "凯莱英拟将不超16亿元暂时闲置募集资金进行现金管理",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "募集资金",
                        "现金管理"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-11-01",
                "original_text": "高瓴、高毅、景林三季度以来持仓曝光 医药、安防“榜上有名”",
                "features": {
                    "keywords": [
                        "高瓴",
                        "高毅",
                        "景林",
                        "医药",
                        "安防"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "安防"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-11-01",
                "original_text": "凯莱英定增一波三折终成行 发行价翻倍高瓴坚定布局A股医药版图",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "定增",
                        "高瓴",
                        "医药"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-11-01",
                "original_text": "美的、宁德时代、凯莱英等标的创历史新高，北向资金回马枪扫货A股剑指这些板块！",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "北向资金",
                        "医药",
                        "历史新高"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}